Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5H7N3 |
Molecular Weight | 109.1294 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1c[nH]cc(c1=N)N
InChI
InChIKey=OYTKINVCDFNREN-UHFFFAOYSA-N
InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)
Amifampridine (Firdapse), currently approved in the European Union, is the first and only approved drug for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, a rare autoimmune disease with the primary symptoms of muscle weakness. In LEMS, the body’s own immune system attacks connections between nerves and muscles and disrupts the ability of nerve cells to send signals to muscle cells. Amifampridine blocks voltage-dependent potassium channels, thereby prolonging pre-synaptic cell
membrane depolarization. Prolonging the action potential enhances the transport of calcium into the nerve
ending. The resulting increase in intracellular calcium concentrations facilitates exocytosis of acetylcholine containing
vesicles, which in turn enhances neuromuscular transmission. Amifampridine phosphate has been granted Orphan Drug Designation and Breakthrough Therapy designation by the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21975066 | https://www.ncbi.nlm.nih.gov/pubmed/6744035
Curator's Comment:: Amifampridine (3,4-DAP) displays toxicity largely due to blood-brain-barrier (BBB) penetration.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
59.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26101174/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMIFAMPRIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
40.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26101174/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMIFAMPRIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
189 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26101174/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
3-N-ACETYL-AMIFAMPRIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
268 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26101174/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
3-N-ACETYL-AMIFAMPRIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
117 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26101174/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMIFAMPRIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
109 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26101174/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMIFAMPRIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1220 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26101174/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
3-N-ACETYL-AMIFAMPRIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1444 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26101174/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
3-N-ACETYL-AMIFAMPRIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26101174/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMIFAMPRIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.28 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26101174/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMIFAMPRIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4.03 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26101174/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
3-N-ACETYL-AMIFAMPRIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26101174/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
3-N-ACETYL-AMIFAMPRIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
healthy, adult n = 52 Health Status: healthy Age Group: adult Population Size: 52 Sources: |
Other AEs: Paresthesia, Dysesthesia... Other AEs: Paresthesia (69%) Sources: Dysesthesia (69%) Oral dysesthesia (69%) Abdominal pain (25%) Upper abdominal pain (25%) Dyspepsia (17%) Dizziness (12%) Nausea (10%) Back pain (8%) Hypoesthesia (6%) Muscle spasms (6%) |
75 mg 1 times / day multiple, oral (typical) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 162 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 162 Sources: |
Other AEs: Convulsion, Head titubation... Other AEs: Convulsion (0.6%) Sources: Head titubation (0.6%) Tremor (0.6%) Unresponsive to stimuli (0.6%) Small cell lung cancer (0.6%) Metastases to central nervous system (0.6%) Lung cancer metastatic (0.6%) Pulmonary mass (0.6%) Bradycardia (0.6%) Pneumonia (0.6%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea | 10% | 10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
healthy, adult n = 52 Health Status: healthy Age Group: adult Population Size: 52 Sources: |
Dizziness | 12% | 10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
healthy, adult n = 52 Health Status: healthy Age Group: adult Population Size: 52 Sources: |
Dyspepsia | 17% | 10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
healthy, adult n = 52 Health Status: healthy Age Group: adult Population Size: 52 Sources: |
Abdominal pain | 25% | 10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
healthy, adult n = 52 Health Status: healthy Age Group: adult Population Size: 52 Sources: |
Upper abdominal pain | 25% | 10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
healthy, adult n = 52 Health Status: healthy Age Group: adult Population Size: 52 Sources: |
Hypoesthesia | 6% | 10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
healthy, adult n = 52 Health Status: healthy Age Group: adult Population Size: 52 Sources: |
Muscle spasms | 6% | 10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
healthy, adult n = 52 Health Status: healthy Age Group: adult Population Size: 52 Sources: |
Dysesthesia | 69% | 10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
healthy, adult n = 52 Health Status: healthy Age Group: adult Population Size: 52 Sources: |
Oral dysesthesia | 69% | 10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
healthy, adult n = 52 Health Status: healthy Age Group: adult Population Size: 52 Sources: |
Paresthesia | 69% | 10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
healthy, adult n = 52 Health Status: healthy Age Group: adult Population Size: 52 Sources: |
Back pain | 8% | 10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
healthy, adult n = 52 Health Status: healthy Age Group: adult Population Size: 52 Sources: |
Bradycardia | 0.6% | 75 mg 1 times / day multiple, oral (typical) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 162 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 162 Sources: |
Convulsion | 0.6% | 75 mg 1 times / day multiple, oral (typical) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 162 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 162 Sources: |
Head titubation | 0.6% | 75 mg 1 times / day multiple, oral (typical) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 162 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 162 Sources: |
Lung cancer metastatic | 0.6% | 75 mg 1 times / day multiple, oral (typical) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 162 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 162 Sources: |
Metastases to central nervous system | 0.6% | 75 mg 1 times / day multiple, oral (typical) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 162 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 162 Sources: |
Pneumonia | 0.6% | 75 mg 1 times / day multiple, oral (typical) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 162 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 162 Sources: |
Pulmonary mass | 0.6% | 75 mg 1 times / day multiple, oral (typical) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 162 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 162 Sources: |
Small cell lung cancer | 0.6% | 75 mg 1 times / day multiple, oral (typical) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 162 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 162 Sources: |
Tremor | 0.6% | 75 mg 1 times / day multiple, oral (typical) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 162 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 162 Sources: |
Unresponsive to stimuli | 0.6% | 75 mg 1 times / day multiple, oral (typical) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 162 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 162 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208078Orig1s000PharmR.pdf#page=27 Page: 27.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208078Orig1s000PharmR.pdf#page=27 Page: 27.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208078Orig1s000PharmR.pdf#page=27 Page: 27.0 |
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208078Orig1s000PharmR.pdf#page=26 Page: 26.0 |
||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208078Orig1s000PharmR.pdf#page=26 Page: 26.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Validation of a CE assay for the analysis of isomeric aminopyridines and diaminopyridines. | 2001 Feb |
|
Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. | 2001 Feb-Mar |
|
Theoretical analysis of the molecular determinants responsible for the K(+) channel blocking by aminopyridines. | 2001 Jun 15 |
|
Aminopyridines for symptomatic treatment in multiple sclerosis. | 2002 |
|
Improvement of dy/dy dystrophic diaphragm by 3,4-diaminopyridine. | 2002 Jul |
|
Treatment for Lambert-Eaton myasthenic syndrome. | 2003 |
|
Wheel-running exercise alters rat diaphragm action potentials and their regulation by K+ channels. | 2003 Aug |
|
Electrophysiological and pharmacological characterization of K+-currents in muscle fibres isolated from the ventral sucker of Fasciola hepatica. | 2004 Dec |
|
Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. | 2004 Jun 8 |
|
NCAM 180 acting via a conserved C-terminal domain and MLCK is essential for effective transmission with repetitive stimulation. | 2005 Jun 16 |
|
Taicatoxin inhibits the calcium-dependent slow motility of mammalian outer hair cells. | 2005 May |
|
Fetal exposure to 3,4-diaminopyridine in a pregnant woman with congenital myasthenia syndrome. | 2006 Apr |
|
Inotropic effects of the K+ channel blocker 3,4-diaminopyridine: differential responses of rat soleus and extensor digitorum longus. | 2006 Dec |
|
[Fatigue and episodic exhaustion as a feature of multiple sclerosis]. | 2006 Mar |
|
Childhood myasthenia: clinical subtypes and practical management. | 2007 Aug |
|
Beneficial effects of 3,4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion. | 2007 Aug |
|
Myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient. | 2007 Jul |
|
[Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine]. | 2007 Jul-Aug |
|
Molecular docking study of the binding of aminopyridines within the K+ channel. | 2007 May |
|
Long-lasting in vivo inotropic effects of the K(+) channel blocker 3,4-diaminopyridine during fatigue-inducing stimulation. | 2008 Dec |
|
[Lambert-Eaton Myasthenic Syndrome associated with vocal cord carcinoma]. | 2008 Jan |
|
Autoantibodies in neuromuscular transmission disorders. | 2008 Jul |
|
Onset dynamics of type A botulinum neurotoxin-induced paralysis. | 2008 Jun |
|
Therapeutic strategies in congenital myasthenic syndromes. | 2008 Oct |
|
[A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine]. | 2009 Jan |
|
3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. | 2009 Nov |
|
3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study. | 2010 Jun |
Sample Use Guides
Amifampridine (Firdapse) should be given in divided doses, three or four times a day. The recommended starting dose is
15 mg a day, which can be increased in 5 mg increments every 4 to 5 days, to a maximum of 60 mg per day.
No single dose should exceed 20 mg.
Tablets are to be taken with food.
For oral use only.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8358554
In nerve terminal regions of axons in rat olfactory cortex in the presence of tetraethylammonium (TEA, 5 mM) and Cd2+ (100 uM), the K(+)-component was depressed by Amifampridine (3,4-DAP; 1 to 20 uM; IC50 2.0 +/- 0.4 uM).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
56090
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
||
|
WHO-ATC |
N07XX05
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
||
|
WHO-VATC |
QN07XX05
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
||
|
NDF-RT |
N0000192795
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
||
|
FDA ORPHAN DRUG |
299909
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
||
|
NCI_THESAURUS |
C93038
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
||
|
FDA ORPHAN DRUG |
43189
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
||
|
FDA ORPHAN DRUG |
556516
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
FIRDAPSE (AUTHORIZED: LAMBERT-EATON MYASTHENIC SYNDROME)
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
||
|
FDA ORPHAN DRUG |
51590
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL354077
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
2106338
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
200-220-9
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
RU4S6E2G0J
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
C82687
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
3,4-DIAMINOPYRIDINE
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
8032
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
SUB28846
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
Amifampridine
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
C016361
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
M1668
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | Merck Index | ||
|
54-96-6
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
8804
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
54-96-6
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
5918
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
4336
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY | |||
|
DB11640
Created by
admin on Sat Jun 26 06:11:22 UTC 2021 , Edited by admin on Sat Jun 26 06:11:22 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE INACTIVE (PARENT)
SALT/SOLVATE (PARENT)